Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity

Kuniaki Tsutsumi, Takanori Kaname, Haruka Shiraishi, Takehiro Kawashiri, Nobuaki Egashira

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.

元の言語英語
ページ(範囲)146-149
ページ数4
ジャーナルJournal of Pharmacological Sciences
131
発行部数2
DOI
出版物ステータス出版済み - 6 1 2016

Fingerprint

polaprezinc
Peripheral Nervous System Diseases
Paclitaxel
Neoplasms
Hyperalgesia
Spinal Ganglia
Cultured Cells
Macrophages
Cell Line

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology

これを引用

Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity. / Tsutsumi, Kuniaki; Kaname, Takanori; Shiraishi, Haruka; Kawashiri, Takehiro; Egashira, Nobuaki.

:: Journal of Pharmacological Sciences, 巻 131, 番号 2, 01.06.2016, p. 146-149.

研究成果: ジャーナルへの寄稿記事

@article{794c050acd8d4646ad14967016c88fed,
title = "Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity",
abstract = "Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.",
author = "Kuniaki Tsutsumi and Takanori Kaname and Haruka Shiraishi and Takehiro Kawashiri and Nobuaki Egashira",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.jphs.2016.04.019",
language = "English",
volume = "131",
pages = "146--149",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "2",

}

TY - JOUR

T1 - Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity

AU - Tsutsumi, Kuniaki

AU - Kaname, Takanori

AU - Shiraishi, Haruka

AU - Kawashiri, Takehiro

AU - Egashira, Nobuaki

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.

AB - Paclitaxel, an anticancer drug, frequently causes painful peripheral neuropathy. In this study, we investigated the preventive effect of polaprezinc on paclitaxel-induced peripheral neuropathy in rats. Polaprezinc (3 mg/kg, p.o., once daily) inhibited the development of mechanical allodynia induced by paclitaxel (4 mg/kg, i.p., on days 1, 3, 5 and 7) and suppressed the paclitaxel-induced increase in macrophage migration in dorsal root ganglion cells. In addition, polaprezinc did not affect the anti-tumor activity of paclitaxel in cultured cell lines or tumor-bearing mice. These results suggest a clinical indication for polaprezinc in the prevention of paclitaxel-induced neuropathy.

UR - http://www.scopus.com/inward/record.url?scp=84973861918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973861918&partnerID=8YFLogxK

U2 - 10.1016/j.jphs.2016.04.019

DO - 10.1016/j.jphs.2016.04.019

M3 - Article

C2 - 27262900

AN - SCOPUS:84973861918

VL - 131

SP - 146

EP - 149

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 2

ER -